Medicare/Medicaid might pay for GLP1s again
GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
It’s simple — if more people can afford GLP-1s (possibly as part of a subsidized program) more companies are incentivized to continue making, innovating on and distributing GLP1s, and that’s great for society as a whole.
This news was first reported on by the Washington Post:
Below, we’ll dive in to a quick summary of what happened and how we think it’ll change the landscape.
🏛️ What is the White House proposing?
The White House wants to move the responsibility of evaluating GLP-1s for coverage under Medicare/Medicaid to the Center for Medicare and Medicaid Innovation (CMMI).
This means that the CMMI would create a pilot program to investigate the efficacy and efficiency of GLP-1s relative to cost. If successful that would then lead to longer term changes to the availability of the drug under medicare/medicaid.
There's more to this post, but it's not available here. This article is fresh for subscribers – if you'd like to read the rest of our analysis, check us out on Substack:
